Foster & Motley Inc. Grows Stock Position in Pacira BioSciences, Inc. $PCRX

Foster & Motley Inc. increased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 172.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,057 shares of the company’s stock after purchasing an additional 25,984 shares during the quarter. Foster & Motley Inc. owned 0.10% of Pacira BioSciences worth $1,063,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hantz Financial Services Inc. raised its position in Pacira BioSciences by 175.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock worth $29,000 after buying an additional 721 shares during the last quarter. Tidemark LLC acquired a new stake in shares of Pacira BioSciences in the 3rd quarter worth $56,000. Strs Ohio purchased a new stake in shares of Pacira BioSciences in the first quarter valued at about $75,000. iSAM Funds UK Ltd purchased a new stake in shares of Pacira BioSciences in the third quarter valued at about $80,000. Finally, Vestcor Inc acquired a new position in shares of Pacira BioSciences during the third quarter worth about $90,000. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $22.79 on Thursday. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54. Pacira BioSciences, Inc. has a 52-week low of $18.80 and a 52-week high of $27.64. The company has a 50-day simple moving average of $22.07 and a 200-day simple moving average of $23.29. The company has a market capitalization of $922.77 million, a PE ratio of 151.93 and a beta of 0.21.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The company had revenue of $196.87 million for the quarter, compared to analysts’ expectations of $201.93 million. During the same period in the prior year, the firm posted $0.91 EPS. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. Equities research analysts predict that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on PCRX shares. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a report on Friday, January 9th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a research note on Monday, December 29th. Zacks Research cut Pacira BioSciences from a “hold” rating to a “strong sell” rating in a report on Monday, March 9th. Finally, Barclays decreased their price target on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $30.25.

Insider Activity at Pacira BioSciences

In other news, SVP Lauren Riker sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the sale, the senior vice president owned 52,313 shares of the company’s stock, valued at $1,088,633.53. The trade was a 7.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jonathan Slonin sold 3,261 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total value of $74,416.02. Following the completion of the sale, the insider owned 223,640 shares in the company, valued at approximately $5,103,464.80. This represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,677 shares of company stock worth $191,980 in the last three months. Corporate insiders own 6.40% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.